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Summary
A strategy to improve allergen-specific immunotherapy is to employ new
adjuvants stably linked to allergens. The study is addressed to evaluate
the in vivo and in vitro effects of allergens [natural Dermatophagoides
pteronyssinus 2 (nDer p 2) and ovalbumin (OVA)] chemically bound to
an 8-OH-modified adenine. Humoral and cellular responses were analysed
in allergen-sensitized and challenged mice by using conjugates (Conj) in a
therapeutic setting. The in vitro activity of the conjugates on cytokine
production induced by bone marrow dendritic cells and the co-culture
system was also investigated. The nDer p 2-Conj treatment in nDer p 2-
primed and challenged BALB/c mice reduced the numbers of eosinophils
in bronchoalveolar lavage fluid and lung, airway allergen-driven interleu-
kin-13 (IL-13) production in lung mononuclear cells and IgE, in compari-
son with nDer p 2-treated mice. The increase of IgG2a paralleled that of
interferon-c (IFN-c) and IL-10 in allergen-stimulated spleen cells. Similar
effects were elicited by treatment with OVA-Conj in an OVA-driven
BALB/c model. The nDer p 2-Conj or OVA-Conj redirected memory T
helper type 2 cells towards the production of IL-10 and IFN-c also in
C57BL/6 mice and when subcutaneously administered. Interleukin-10,
IL-12 and IL-27 were produced in vitro by Conj-stimulated bone marrow
dendritic cells, whereas IL-10 and IFN-c were up-regulated in co-cultures
of CD11c+ and CD4+ T cells from Conj-treated mice stimulated with
allergen. Cytofluorometric analysis indicated that the Conj expanded IFN-
c- and IL-10- producing memory T cells. The Conj effects on IL-10/
and IL-12/ mice confirmed the role of IL-10 and IFN-c in inducing a
protective and balanced redirection the T helper type 2-mediated airway
inflammation.
Keywords: adenine derivatives; adjuvants; immunotherapy; toll-like recep-
tors; vaccines
Introduction
Although steroids, antihistamines and immunosuppres-
sors usually control allergic diseases, specific immuno-
therapy is the only treatment able to modify the
pathogenic mechanisms of these disorders. However, as
this treatment is inefficacious in a high percentage of
patients,1 several approaches are under investigation to
increase the efficiency of this procedure, including opti-
mization of antigens, new administration routes and
novel adjuvants.2–4 Among new adjuvants the use of
low-molecular-weight synthetic compounds triggering
Abbreviations: BALF, bronchoalveolar lavage fluid; BMDC, bone marrow dendritic cells; Conj, conjugate; DC, dendritic cell;
IFN, interferon; IL, interleukin; MNC, mononuclear cells; nDer p 2, natural Dermatophagoides pteronyssinus group 2 major aller-
gen; OVA, ovalbumin; PAS, periodic acid Schiff; Th, T helper; TLR, toll-like receptor
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endosomal Toll-like receptor (TLR) on dendritic cells
(DC) has been proposed.5,6 Notably, the soluble ligands
of endosomal TLR, in particular of TLR7, have been
described as inducing in vivo autoantibodies and playing
a still unclear role in autoimmunity.7,8 The chemical
binding of allergens with adjuvant improves the activity
of the constructs because it allows the delivery of the two
components inside the same antigen-presenting cell with
the outgrowth of the innate response redirecting the T
helper type 2 (Th2) response. Hence the conjugate (Conj)
with endosomal TLR ligands should increase safety by
avoiding chronic B-cell activation and the onset of
autoimmunity.9 The vaccination with the conjugate
between ovalbumin (OVA) and 3M042 (an imidazoquin-
oline compound triggering TLR7/8) exerted a shift to a
Th1 response, promoting antigen uptake by resident and
migratory DC subsets.10 In atopic patients the major
allergen in ragweed pollen (Amb a 1) stably bound to a
22-mer oligodesossinucleotide sequence (a TLR9 ligand)
associated with improvement of symptoms, decreased
IgE, produced a transient increase of specific IgG and,
locally, eosinophils and Th2 cells.11
We have previously shown that the mixture of an anti-
gen with 2-,9-substituted 8-OH adenines influences the
profile of T effector cells both in humans and mice.12,13
The Conj between SA26E, an 8-OH modified adenine
triggering TLR7 in human and murine cells, and the natu-
ral group 2 major allergen (nDer p 2) from Dermatophago-
ides pteronyssinus was able to redirect allergen-specific Th2
responses in vitro and prevent the development of airway
inflammation in vivo.14
The aim of this study was to evaluate the activity on
murine airway inflammation of two (nDer p 2 and OVA)
conjugates in a therapeutic setting and to establish their
mechanism of action. Even though some different effects
were related to the structure of the two allergens, to mouse
strain and to administration route, the results show that
these novel conjugates deeply impair airway inflammation
when administered in allergen-sensitized and challenged
mice. The in vitro and in vivo data indicate that the major
activity of these new compounds is to up-regulate and
expand interferon-c (IFN-c) and interleukin-10 (IL-10) -
producing memory T cells, a protective and balanced cyto-
kine profile redirecting the allergen-specific Th2 response.
Materials and methods
Reagents
The LoToxTM nDer p 2 used throughout the study was
purchased from Indoor Biotechnologies Ltd. (batch no.
31059) (Charlottesville, VA) and certified to contain
< 003 EU/lg endotoxin. Low-endotoxin RPMI-1640
medium (VLE-RPMI 1640; Biochrom AG, Berlin,
Germany) was supplemented with low endotoxin 2 mM
L-glutamine, 2 mM 2-mercaptoethanol, 100 U/ml penicil-
lin and 100 lg/ml streptomycin (all from Sigma Chemical
Co, Milan, Italy) (complete medium). Fetal calf serum
was from HyClone (Thermo Scientific, Milan, Italy). Both
PMA and ionomycin were purchased from Sigma-Aldrich
(Milan, Italy). OVA and R-848 (Resiquimod, S28463)
were from Invivogen (Milan, Italy). The endotoxin con-
tent of all the final reagents (allergens, SA26E and their
conjugates) before use was assessed by LAL Test (Bio-
Whittaker, Walkersville, MD), which was consistently
lower than the detection limit of the assay. Anti-murine
CD3 [phycoerythrin-allophycocyanin-conjugated (PE-
APC)], CD4 (APC-FITC) and CD8 (PE) monoclonal
antibodies were purchased from Miltenyi Biotec (Bergisch
Gladbach, Germany). Anti-murine IFN-c (FITC) and
anti-murine IL-13 (PE) were purchased from eBioscience
(San Diego, CA). Anti-murine IL-10 (PE) was purchased
from Becton-Dickinson (Mountain View, CA).
Synthesis of SA26E, preparation of OVA- and nDer
p 2-Conj and stimulation of TLR-transfected HEK293
SA26E synthesis and its binding to OVA (or nDer p 2) were
performed as previously described.14 Briefly, SA26E was dis-
solved in 130 ll DMSO (Sigma-Aldrich) and chemically con-
jugated with 3 mg of purified OVA or 15 mg of nDer p 2 in
phosphate buffer (to final volumes of 15 and 3 ml, respec-
tively) by overnight incubation at 4° with continuous rota-
tion. Unconjugated SA26E was then removed by repeated
dialysis (2000 molecular weigh cut-off, Slyde-A-Lyzer cas-
settes; Pierce, Rockford, IL) with PBS. Conjugates were
divided into aliquots and stored at20° until use.
HEK293 were transiently transfected with murine TLR7
and ELAM-1 promoter nuclear factor-jB luciferase or
with ELAM-1 promoter nuclear factor-jB luciferase alone
reporter plasmid.14 After transfection, cells were plated in
48 flat-bottomed plates in D-MEM (Sigma-Aldrich) sup-
plemented with 2 mM L-glutamine and 5% FCS for 18 hr
and then stimulated with R848 (6 lM), SA26E (2 lg),
allergen (10 lg/ml) and allergen-Conj (10, 2 and 0.4 lg/
ml) for an additional 18 hr. At the end of the culture,
luciferase activity was determined in cell lysates by a lucif-
erase Assay System (Promega, Madison, WI) (see Supple-
mentary material, Fig. S1).
Mice
Interleukin-10-deficient mice (B6.129P2-Il10tm1Cgn/J; stock
#002251) and IL-12-deficient mice (B6.129S1-Il12atm1Jm/J;
stock # 002692) were obtained from the Jackson Laboratory
(Bar Harbor, ME). Both strains are on the C57BL/6 back-
ground. Female 6- to 8-week-old BALB/c and C57BL/6
mice were purchased from Charles River (Calco, Italy) and
the animal study protocol was approved by the Institutional
National guidelines and local animal ethics regulations.
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In vivo therapeutic models
Mice were intraperitoneally sensitized at days 0 and 7
with 100 ll PBS containing nDer p 2 or OVA (10 lg)
adsorbed onto 225 lg Alum (Imject; Pierce). Negative
controls were sham sensitized with PBS in Alum. Mice
were challenged intratracheally at day 14 by administra-
tion of nDer p 2 (10 lg in 50 ll of PBS) or PBS (nega-
tive control). Treatment consisted of administration of
nDer p 2-Conj (intraperitoneally) or OVA-Conj (intra-
peritoneally or subcutaneously) or the corresponding
allergen (10 lg in 100 ll of PBS), at 21, 23, 26 and
28 days. After the last administration of the adduct, mice
were intratracheally re-challenged with allergens at 49
and 53 days and killed 3 days later for analysis
(Fig. 1).15–17
Bronchoalveolar lavage
Bronchoalveolar lavage (BAL) was performed as previ-
ously described.13 BAL cells were morphologically charac-
terized by Diff-Quick.
Lung histology
Lung sections were stained with haematoxylin and eosin
and periodic acid Schiff (PAS) to evaluate lung inflamma-
tion, eosinophilic infiltration and goblet cell hyperplasia
using previously described scores.14,18
Generation of bone marrow dendritic cells
Bone marrow dendritic cells (BMDC) were prepared
according to well-defined protocols19 and cultured in vitro
at day 8 for 6 hr (mRNA detection) and 72 hr (protein
detection) with OVA or nDer p 2 (10 lg/ml), OVA-Conj
or nDer p 2-Conj (10 lg/ml), or medium alone. At the
end of the cultures, the cells were collected for total RNA
extraction and supernatants were assayed for their IL-10,
IL-12, IL-27, IL-1b, IL-23, CXCL10, IL-25, IL-6 and IFN-
a content.
CD11c+ and CD4+ isolation and co-cultures
Dendritic cells and CD4+ T cells were purified from
spleens of nDer p 2- or Conj-treated C57BL/6 mice by
positive selection with anti-CD11c monoclonal antibodies
bound to MACS Microbeads and a CD4+ T-cell Isolation
kit (Miltenyi Biotec) according to the manufacturer’s
instructions. The enrichment of isolated cells examined
by cytometry was consistently > 95%. In the co-culture
system purified CD11c+ spleen cells were co-cultured with
purified CD4+ T cells (CD11c+ : CD4+ cell ratio 1 : 4) in
the presence of medium or allergen or allergen-Conj at
the final concentration of 50 lg/ml for 12 hr (mRNA
detection) and 72 hr (protein detection).
Interleukin-10, IFN-c and IL-13 production by co-cul-
tures and purified CD4+ T cells was evaluated in flow
cytometry with anti-CD3 APC, anti-IL-10 PE, anti-IFN-c
FITC and IL-13 PE. Stained cells were analysed on a BD-
FACSCanto flow cytometer using the DIVATM software
(Becton Dickinson), as described previously.12
ELISA
Lung, spleen and mediastinal lymph node mononuclear
cells (MNC) were prepared and cultured with allergens as
previously described.13 Three-day culture supernatants
were used for evaluating IFN-c, IL-10 and IL-13 mea-
sured by commercial ELISA kits (R&D Systems, Minne-
apolis, MN) according to the manufacturer’s instructions.
Detection limits for IFN-c, IL-10 and IL-13 were 2, 4 and
15 pg/ml, respectively. BMDC stimulated with conjugates
were assayed by commercially available ELISA kits (R&D
Systems). Detection limits of IL-12, IL-27, IL-1b, IL-23,
CXCL10, IL-25, IL-6 and IFN-a kits were 75, 19, 75,
48, 417, 42, 18 and 125 pg/ml, respectively.
Total and OVA-specific IgE, allergen-specific IgG1 and
IgG2a antibodies were measured by ELISA as described.18
Quantitative mRNA analysis
Total lung RNA from snap-frozen mouse lungs were
extracted using TRIzol reagent (RNAwiz; Invitrogen,
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Figure 1. Experimental protocol. Sensitization,
challenge, treatment and analysis timing in a
murine model of airway inflammation. i.p.,
intraperitoneal; i.t., intratracheal; s.c., subcuta-
neous; Ag, allergen; : blood sampling.
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Milan, Italy), whereas total RNA from MNC were
extracted using the RNeasy mini kit (Qiagen, Milan,
Italy) as previously described.14 Real-time quantitative
PCR was performed on an ABI PRISM 7700 Sequence
Detector (Applied Biosystems, Warrington, UK) with
Applied Biosystems predesigned TaqMan Gene Expression
assays and reagents according to the manufacturer’s
instructions.
Statistical analysis
Statistical analysis was performed using Student’s t-test
and analysis of variance (with Bonferroni correction). P
values < 005 were considered significant.
Results
nDer p 2-Conj improves airway inflammation in a
therapeutic setting
We assayed the effects of nDer p 2-Conj administration in
allergen-immunized and challenged BALB/c mice, usually
prone to induce a Th2-oriented response, using the thera-
peutic protocol described in the Fig. 1. Mice treated with
nDer p 2-Conj showed a significant reduction of numbers
of eosinophils and neutrophils in BAL fluid (BALF), with
no changes of lymphocytes compared with nDer p 2-trea-
ted control mice (Fig. 2a). The lung histology indicated a
reduced proportion of infiltrating eosinophils in both
perivascular and peribronchial lung compartments of
nDer p 2-Conj-treated mice (Fig. 2b). In the lung, the
mRNA expression of the mucin-related gene GOB-5, as
well as the PAS+ cellular scores, were reduced, but not sig-
nificantly (see Supplementary material, Fig S2). Allergen-
stimulated MNC from lung and mediastinal lymph nodes
of nDer p 2-Conj-treated mice showed significant reduc-
tion of IL-13, with unchanged IFN-c and IL-10 compared
with MNC obtained from nDer p 2-treated mice (Fig. 2c
left panel and data not shown). The reduction of IL-13
was however associated with the significant increase of
mRNA expression of IFN-c and IL-10 in spleen MNC
(Fig. 2c right panel). Finally, in nDer p 2-Conj-treated
mice, total IgE and nDer p 2-specific IgG1 were signifi-
cantly reduced compared with nDer p 2-treated animals
(Fig. 2d,e left panel), whereas allergen-specific IgG2a was
significantly increased (Fig. 2e right panel).
OVA-Conj decreases airway inflammation in OVA-
sensitized mice
We then asked whether another allergen (OVA), stably
coupled to the same 8-OH-modified adenine, would dis-
play the in vivo effects described with nDer p 2-Conj in a
therapeutic setting in BALB/c strain.
As established for nDer p 2-Conj,14 we initially
showed that OVA-Conj was able to selectively stimulate
TLR7-transfected HEK293 cells. Indeed the conjugates,
but not the allergen alone, induced nuclear factor-jB
activity in transfected cells (see Supplementary material,
Fig. S1).
We showed a significant reduction of the proportion
but not the number of eosinophils in BALF of OVA-
Conj-treated mice in comparison to OVA-treated animals
(4035  051% versus 2985  392% P < 002)
(Fig. 3a). The conjugate had no effects on the proportion
and numbers of other inflammatory cells in BALF
(Fig. 3a). In addition, the treatment reduced the numbers
of eosinophils in both peribronchial and perivascular lung
compartments (Fig. 3b). In the lung, the GOB-5 mRNA
expression, as well as the PAS+ cellular scores, were
reduced, even though not significantly (see Supplemen-
tary material, Fig. S2). Upon OVA stimulation, MNC
from lung and mediastinal lymph nodes from OVA-
Conj-treated mice showed significantly increased IFN-c
and decreased IL-13 compared with OVA-treated mice
(Fig. 3c and data not shown). The OVA-Conj treatment
decreased total and OVA-specific IgE and significantly
increased allergen-specific IgG2a with no change of aller-
gen-specific IgG1 (Fig. 3d,e).
The mouse strain and the route of administration do
not influence the Conjugates’ effects
To establish whether the redirection of the allergen-spe-
cific Th2 response to a more protective Th cell profile
(IFN-c and IL-10 production) was a general phenome-
non, we performed the same experimental protocol with
both compounds in C57BL/6 strain. nDer p 2- and OVA-
Conj-treated C57BL/6 mice showed the same modifica-
tions as described for Conj-treated BALB/c mice
(decreased numbers of eosinophils in BALF and lung,
PAS infiltration scores, serum total IgE and allergen-spe-
cific IgG1 and increased allergen-specific IgG2a) (Fig. 4a
and see Supplementary material, Fig. S2 and data not
shown). Importantly, in these mice IFN-c and IL-10 pro-
duction by lung, mediastinal lymph nodes and spleen
MNC upon the corresponding allergen stimulation were
significantly increased and associated with a reduction
(significant in nDer p 2 but not in OVA model) of IL-13
(Fig. 4b).
To evaluate the effect of changing the route of adminis-
tration, the subcutaneous injection of the conjugate was
performed. In OVA-sensitized and challenged BALB/c or
C57Bl/6 mice, the subcutaneous treatment with OVA-
Conj induced increased IFN-c and IL-10 production by
OVA-stimulated lung MNC compared with OVA-treated
mice (Fig. 5a). These results paralleled the significant
increase of specific IgG2a (Fig. 5b).
ª 2015 The Authors. Immunology published by John Wiley & Sons Ltd., Immunology4
F. Nencini et al.
The conjugates induce pro-inflammatory and
regulatory cytokines in vitro
To study the mechanisms down-regulating airway
inflammation, we evaluated the activity of conjugates on
antigen-presenting cells in vitro. BMDC generated from
wild-type BALB/c mice were cultured in vitro with nDer p 2-
and OVA-Conj or the corresponding allergens. The conju-
gates induced higher levels of IL-10, IL-12, IL-27 (at the
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Figure 2. The nDer p 2-Conj down-regulates allergen-induced airway inflammation in BALB/c mice. (a) Differential cell counts in bronchoalveo-
lar lavage fluid (BALF) performed 72 hr after the last challenge. (b) Eosinophil infiltration in lung compartments (PV, perivascular; PB, peribron-
chial; ALV, alveolar). (c) Cytokine production by lung mononuclear cells (MNC) upon in vitro nDer p 2 stimulation (left panel) and cytokine
mRNA expression in spleen MNC (right panel). (d, e) Detection of total IgE and allergen-specific IgG1 and IgG2a. All reported data are referred
to pooled results from three separate experiments; six mice/group. Data are expressed as the mean ( SEM) and statistical significance between
the allergen and allergen-Conj groups is reported. *P < 005, **P < 001.
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mRNA and protein levels) than those elicited by allergens
alone (Table 1). BMDC generated from wild-type C57BL/6
mice gave similar results (data not shown). Other secreted
molecules such as IL-1b, IL-23, CXCL10 were up-regulated
in BMDC stimulated by both conjugates whereas IL-6, IL-25
and type I IFN were unaffected (data not shown).
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Figure 3. Effects of ovalbumin (OVA)-Conj treatment in BALB/c mice. (a) Differential cell counts in bronchoalveolar lavage fluid (BALF)
performed 72 hr after the last challenge. (b) Eosinophil infiltration in lung compartments (PV, perivascular; PB, peribronchial; ALV, alve-
olar) (c) Cytokine production upon in vitro OVA stimulation of lung mononuclear cells (MNC). (d, e) Detection of total IgE and aller-
gen-specific IgE, IgG1 and IgG2a. All reported data refer to pooled results from three separate experiments; six mice/group. Data are
expressed as the mean ( SEM) and statistical significance between the allergen and allergen-Conj groups is reported. *P < 005,
***P < 0001.
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The in vivo effects of conjugates require the
production of both IFN-c and IL-10
To better define the role of inflammatory and regulatory
cytokines, we compared the in vivo effects of
nDer p 2-Conj treatment in IL-10/ and IL-12/ mice.
In IL-10/ mice, specific IgG2a was significantly
increased and total IgE was inhibited in nDer p 2-Conj-
treated mice compared with nDer p 2-treated mice,
whereas the IgG1 was unchanged. In IL-12/ mice,
nDer p 2-Conj treatment significantly increased IgE and
allergen-specific IgG1 compared with allergen-treated
mice (Fig. 6a).
The proportions and numbers of lymphocytes were sig-
nificantly increased in BALF from nDer p 2-Conj-treated
IL-10/ (29 290  6425 versus 2602  1103, P < 001)
and IL-12/ (12 474  5310 versus 182  119,
P < 005) in comparison with nDer p 2-treated IL-10/
and IL-12/ mice, whereas both eosinophils and neu-
trophils were unchanged (data not shown). Moreover,
lung histological peribronchial and perivascular infiltra-
tion and eosinophil scores were significantly increased in
IL-10/ and IL-12/ Conj-treated mice compared with
allergen-treated mice (Fig. 6b). In addition, PAS score
was significantly higher in Conj-treated than in nDer p 2-
treated IL-12/ mice (1518  0215 versus
0308  0117, P < 001). On the other hand, PAS score
was unchanged in Conj-treated IL-10/ and wt mice
compared with allergen-treated animals (data not shown).
The most important finding is that IFN-c and IL-13 were
strongly up-regulated in the allergen-stimulated MNC
from lung, mediastinal lymph nodes and spleen of
nDer p 2-Conj-treated compared with nDer p 2-treated
IL-10/ mice (Fig. 6b). Of note, these cytokines were
significantly higher than those detected in Conj-treated
IL-12/ mice (Fig. 6c).
Lastly to establish whether the conjugates expand aller-
gen-specific T cells producing IL-10 and IFN-c, we per-
formed co-cultures between purified allergen-pulsed
splenic CD11c+ and CD4+ T cells derived from treated
C57BL/6 mice. As expected, at the mRNA and protein
levels, IL-10 and IFN-c were higher in co-culture super-
natants from nDer p 2-Conj- than nDer p 2-treated mice
(Fig. 7a). Accordingly, the cytometric analysis on the
3-day-cultured CD3-gated cells of the previous
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Figure 4. Effects of conjugates treatment in C57BL/6 mice. (a) Detection of allergen-specific IgG2a in nDer p 2-Conj- (left panel) and ovalbumin
(OVA) -Conj- (right panel) treated mice. (b) Cytokine production by lung mononuclear cells (MNC) upon in vitro allergen stimulation in
nDer p 2-Conj-treated mice (left panel) and OVA-Conj-treated mice (right panel). All reported data refer to pooled results from four separate
experiments; six mice/group. Data are expressed as the mean ( SEM) and the statistical significance between the allergen and allergen-Conj
groups is reported. *P < 005, **P < 001, ***P < 0001.
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experiment indicates a significantly increased proportion
of IL-10- and IFN-c-producing cells in cultures from
Conj-treated mice in comparison with allergen-treated
mice (Fig. 7b). Moreover, upon 6-hr PMA/ionomycin
stimulation the ex vivo purified spleen CD4+ T cells from
nDer p 2-Conj-treated mice also expressed higher propor-
tions of IL-10- and IFN-c-producing cells than those
from control mice (Fig. 7b). In both experimental condi-
tions, IL-13-producing T cells were significantly reduced
in Conj-treated mice (Fig. 7b).
Discussion
Specific immunotherapy represents a relevant approach to
cure respiratory allergy because it is the only treatment
shown to modulate pathogenetic Th2 responses to aller-
gens.20–22 We recently showed that the chemical conjuga-
tion between nDer p 2 and an 8-OH modified adenine
triggering TLR7, called SA26E, is able to improve the vac-
cine construct and to reduce systemic exposure, targeting
appropriate antigen-presenting cells, and so resulting in a
more effective modulation of allergen-specific T-cell
responses.14
In this paper, we provide evidence that the 8-OH-ade-
nine conjugates administered in a therapeutic setting,
mimic the therapeutic effects of specific immunotherapy
in allergic patients by improving airway inflammation in
allergen-sensitized mice, mainly through the up-regula-
tion of IFN-c and IL-10 by memory T cells.
The effects of previously described nDer p 2-Conj in
nDer p 2-sensitized and challenged BALB/c mice, a Th2-
prone strain, induced the impairment of inflammation as
shown by the reduced eosinophils in BALF and lung and
of mucin-secreting cells and their related genes in lung.
Moreover, the significant decrease of type 2 cytokines
(namely IL-13) produced by allergen-stimulated MNC
from lung, mediastinal lymph nodes and spleen in treated
mice reflected the parallel reduction of nDer p 2-specific
IgG1 and total IgE. These data indicate that the
nDer p 2-Conj prevalently inhibits allergen-specific Th2
cells in the lungs of BALB/c mice. These data partially
agree with those of Coffman and co-workers,23 who
described the selective inhibition of a ragweed-specific
Th2 response and IgE in ragweed-primed BALB/c
mice when they were treated intratracheally with a
synthetic TLR9 ligand, without any increase of IFN-c- or
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IL-10-producing cells. In the present paper we confirm
the down-regulation of IL-13 and total IgE upon conju-
gate treatment and we also show that nDer p 2-Conj
shifts the allergen-specific Th2 cells towards an IFN-c-
and IL-10-oriented profile in allergen-stimulated spleen
cells with a parallel significant increase of allergen-specific
IgG2a in the serum. Finally, the nDer p 2-Conj induced
in vitro pro-inflammatory (IL-12 and IL-27) and regula-
tory (IL-10) cytokines by BMDC derived from BALB/c
mice. Taking into account that IFN-c favours the isotype
switch to IgG2a and directly inhibits IgE-producing B
cells, these data suggest that the improvement of airway
inflammation in BALB/c mouse models reflects the redi-
rection of Th2 cells to a protective IFN-c- and IL-10-ori-
ented response rather than the selective inhibition of Th2
cells. Of note, in another strain (C57BL/6) more prone to
favour the Th1 response, we confirmed that nDer p 2-
Conj was mainly associated with the shift of the Th2 cells
towards a pronounced IFN-c and IL-10 cell profile in the
lung.
This concept was confirmed by the data obtained with
another allergen (OVA) bound to the same adjuvant
(SA26E), which triggers lymphoid cells through TLR7.
When OVA-sensitized and challenged BALB/c mice were
treated with OVA-Conj, the decrease of eosinophils in
BALF associated with reduced lung infiltration and eosin-
ophil scores. Importantly, the reduction of total and
OVA-specific IgE in OVA-Conj-treated mice was associ-
ated with the redirection of Th2 to IFN-c-producing cells
in the lung MNC stimulated with OVA, without any
significant increase of IL-10. Again, the imbalance of type
2 and type 1 cytokines was more evident in C57BL/6
mice treated by the same protocol in which, however, the
increase of IL-10 was clearly significant in allergen-stimu-
lated lung MNC. Besides the differences of the mouse
strain, the type of allergens may also influence the in vivo
effects of conjugates. In fact in the same strain (BALB/c)
OVA-Conj-treated mice consistently showed higher levels
of allergen-specific IgG2a than nDer p 2-Conj-treated
mice.
All these findings not only suggest the importance of
the mouse strain used but also reflect the differences
between the two allergens in eliciting the T-cell response.
nDer p 2, a selective inducer of the Th2 response, is
chronically inhaled because the dust mite usually contam-
inates the environment. Hence, nDer p 2 cannot be con-
sidered a neo-antigen, because the in vivo models can be
influenced by the unpredictable inhaled dose of allergen.
By contrast, OVA is more prone to expand IL-4- and
IFN-c-producing T cells and, if administered with adju-
vant, it must be considered a true neo-antigen.13,24
Another important topic of the paper is that the subcu-
taneous administration route, which is traditionally used
in human specific immunotherapy, does not deeply influ-
ence the effects of conjugates. The subcutaneous protocol
with OVA-Conj increased in lung MNC from BALB/c
and C57BL/6 mice both for IFN-c and IL-10 (not signifi-
cantly in C57BL/6) and for allergen-specific IgG2a. Nota-
bly, even though the subcutaneous administration of
antigen has been described to improve the Th17 response
in some in vivo models,25 IL-17A or related cytokines
were never detected in the OVA-stimulated lung MNC by
using the present protocols. This finding agrees with our
previous results that the 8-OH-modified adenine-driven
IL-10 and IL-27 are the best inhibitors of the Th17
response.26
Overall, these data clearly show that these novel conju-
gates improve airway allergic inflammation irrespective of
experimental models by modifying lung and serum
parameters, whose degree is partially influenced by mouse
strain, type of allergens and administration route, as pre-
viously reported.13,27–29
More importantly, regardless of the previous different
conditions employed, the paper provides a clear-cut dem-
onstration that the efficacy of the new compounds resides
in their ability to up-regulate IFN-c and IL-10 in vitro
and in vivo.
By using purified BMDC from wild-type BALB/c and
C57BL/6 mice, we showed that IL-10 and type 1-inducing
(IL-12, IL-27) molecules were highly stimulated by both
conjugates compared with allergens alone. Although the
conjugates in vitro also stimulate IL-1b and IL-23 from
BMDC, two cytokines that are essential to the develop-
ment of Th17 responses, they consistently failed to pro-
mote the in vivo expansion of harmful Th17 cells because,
Table 1. Cytokine mRNA expression and production by bone
marrow dendritic cells from BALB/c mice
Interleukin-10 Interleukin-12 Interleukin-27
(Gene/Ubiquitin)
OVA 04  005 25  04 12  008
OVA-Conj 143  3* 105  1* 23  4*
nDer p 2 05  01 03  001 03  005
nDer p 2-Conj 42  06* 43  12 59  18
Interleukin-10 Interleukin-12 Interleukin-27
(pg/ml)
OVA 75  7 45  25 55  5
OVA-Conj 375  75* 151  50 249  50*
nDer p 2 9  8 75  7 8  6
nDer p 2-Conj 120  30 77  22 150  52
Cytokine mRNA expression was evaluated by real-time quantitative
PCR. Cytokine production was measured using ELISA commercial
kits. Data are expressed as mean values ( SEM) of gene/ubiquitin
ratios or of proteins (above the levels of cultures with medium
alone) in culture supernatants. All reported data are from pooled
results of two separate experiments. Statistical significance between
the allergen and the conjugate group is reported.
*P < 005.
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as previously analysed, they prevalently stimulate IL-17-
inhibiting cytokines as IL-10 and IL-27.26,30
The in vivo results from IL-10/ and IL-12/ mice
clearly indicate that conjugate usually induces a strong
IL-10 production which is not always detectable in differ-
ent models, that partially inhibits IFN-c- and IL-13-pro-
ducing memory T cells. Indeed very high levels of both
IFN-c and IL-13 are produced by allergen-stimulated
MNC from lung, mediastinal lymph nodes and spleen in
nDer p 2-Conj-treated IL-10/ mice, but not by the
same mice treated with allergen alone. Hence in these
mice the up-regulation of IFN-c and IL-13 seems to be a
feature of the conjugate but not of unbound allergen.
Moreover, in Conj-treated IL-10/ mice, the effects of
nDer p 2-driven IFN-c (as the increased allergen-specific
IgG2a, the IgE reduction due to the negative activity of
the cytokine on IgE-producing B cells and the increased
airway infiltration by neutrophils and lymphocytes) par-
tially overcome those of IL-13 (regulating the number of
PAS+ cells and eosinophils in BALF and lung). On the
other hand, in the presence of an IFN-c defect, as in IL-
12/ mice, the IL-10 induced by the conjugate did not
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Figure 7. The conjugate induces interleukin-10
(IL-10) and interferon-c (IFN-c) production by
allergen-stimulated T cells. (a) Cytokine pro-
duction upon in vitro nDer p 2 stimulation in
co-culture between purified spleen CD11c+ and
CD4+ T cells obtained from nDer p 2- or
nDer p 2-Conj-treated C57BL/6 mice (upper
panel). Cytokine mRNA expression in cells
in vitro cultured upon the same experimental
conditions (lower panel). (b) IL-10-, IFN-c-
and IL-13-producing cells in CD3-gated cells
co-cultured as reported in (a) or in purified
CD4+ T cells from Conj- or allergen-treated
mice stimulated with PMA/ionomycin. All
reported data are referred to pooled results
from two separate experiments; six mice/group.
Data are expressed as the mean ( SEM) and
statistical significance between the allergen and
allergen-Conj groups is reported. *P < 005,
**P < 001, ***P < 0001.
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completely block the effects of IL-13 production, as the
increased IgE, eosinophils and PAS+ cells in the lung.
Lastly, the cytofluorimetric analysis on ex vivo purified
CD4+ T cells or in vitro CD3-gated cells from co-cultured
DC and T cells from the treated mice, provides evidence
that the conjugates expand in vivo memory T cells pro-
ducing IL-10 and IFN-c.
Overall these data suggest that conjugate-induced IFN-
c and IL-10 are both essential to ameliorate the airway
inflammation. Indeed, the former may redirect the aller-
gen-mediated type 2 cytokines and IL-10 may quench the
inflammatory effects of IFN-c, potentially being able to
promote autoimmunity.
The effects of Conj-induced IL-10 on Th17 and Th1
responses may explain why conjugates fail to induce au-
toantibodies in short priming14 or long therapeutic set-
tings and to improve spontaneous diabetes in NOD mice
(E. Maggi, unpublished data). The shift of the Th2
response to a protective and balanced T-cell profile is a
valid reason to include the 8-OH-modified adenines
among the other TLR ligands to be bound to allergens in
novel specific immunotherapies.6 The use of conjugates
between proteins linked to these types of adjuvant also
represents a good strategy to design novel vaccine formu-
lations for diseases in which a powerful and balanced
Th1/regulatory type 1 T cell response is required.
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